Progressing factors of nonalcoholic fatty liver disease(NAFLD)by gene analysis of serial liver biopsies.

Progressing factors of nonalcoholic fatty liver disease(NAFLD)by gene analysis of serial liver biopsies. - Progressing factors of nonalcoholic fatty liver disease(NAFLD)by gene analysis of serial liver biopsies.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035231

Enrollment

121

Registered

2018-12-20

Start date

2018-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female over twenty years old 2. NAFLD patients who underwent more than twice liver biopsies from 1998 to December 31, 2017 3. Patients agreeing with the use in genetic analysis when providing existing samples and information 4. Patients who do not refuse participation by the website

Exclusion criteria

Exclusion criteria: 1.Younger than 20 years old

Design outcomes

Primary

Measure	Time frame
To clarify the relationship between hepatic the gene expression by serial liver biopsies and peripheral blood leukocytes in NAFLD patients.	—

Secondary

Measure	Time frame
1) Histological scoring of samples by serial liver biopsies according to Matteoni classification and Brunt classification 2) Analysis of temporal and histological natural history of NAFLD pathology using Linear Mixed Model 3) Diabetic factors (HbA1c, blood biochemistry data, insulin secretory ability, organ-specific insulin resistance determined by hyperinsulinemic euglycemic clamp, organ specific cellular fat accumulation determined by MRS and impedance method, blood hepatocaine level, Diabetes treatment etc.) related to liver pathology 4) Analysis of the hepatic gene expression by serial liver biopsies and peripheral blood leukocytes in NAFLD patients by next-generation sequencing 5) Principal component analysis of genes belonging to metabolic pathways (glycolysis system, fatty acid oxidation, mitochondrial oxidative phosphorylation, etc.) 6) Hepatic gene expression and variable genes in association with NAFLD pathology 7) Identification of SNPs related to change of liver pathology using DNA in peripheral blood cells 8) Analysis of proteins and metabolites in blood by proteomics, metabolomics and lipidomics 9) Measurement of biomarker candidates of NASH such as M2BPGi, ferritin, inflammatory cytokines	—

Measure

Time frame

1) Histological scoring of samples by serial liver biopsies according to Matteoni classification and Brunt classification 2) Analysis of temporal and histological natural history of NAFLD pathology using Linear Mixed Model 3) Diabetic factors (HbA1c, blood biochemistry data, insulin secretory ability, organ-specific insulin resistance determined by hyperinsulinemic euglycemic clamp, organ specific cellular fat accumulation determined by MRS and impedance method, blood hepatocaine level, Diabetes treatment etc.) related to liver pathology 4) Analysis of the hepatic gene expression by serial liver biopsies and peripheral blood leukocytes in NAFLD patients by next-generation sequencing 5) Principal component analysis of genes belonging to metabolic pathways (glycolysis system, fatty acid oxidation, mitochondrial oxidative phosphorylation, etc.) 6) Hepatic gene expression and variable genes in association with NAFLD pathology 7) Identification of SNPs related to change of liver pathology using DNA in peripheral blood cells 8) Analysis of proteins and metabolites in blood by proteomics, metabolomics and lipidomics 9) Measurement of biomarker candidates of NASH such as M2BPGi, ferritin, inflammatory cytokines

—

Countries

Japan

Contacts

Public ContactToshinari Takamura

Department of Endocrinology and Metabolism, Graduate School of Medical Sciences, Kanazawa University Department of Endocrinology and Metabolism

ttakamura@med.kanazawa-u.ac.jp+81762652711

Outcome results